Application of four pricing models for orphan medicines: a case study for lumasiran
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Application of four pricing models for orphan medicines: a case study for lumasiran ; volume:19 ; number:1 ; day:23 ; month:12 ; year:2024 ; pages:1-14 ; date:12.2024
Orphanet journal of rare diseases ; 19, Heft 1 (23.12.2024), 1-14, 12.2024
- Classification
-
Wirtschaft
- Creator
-
Rosenberg, Noa
Manders, Evert
Berg, Sibren van den
Deesker, Lisa J.
Garrelfs, Sander F.
Visser, Saco J. de
Groothoff, Jaap W.
Hollak, Carla E. M.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13023-024-03446-w
- URN
-
urn:nbn:de:101:1-2503032129599.340772743849
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:32 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Rosenberg, Noa
- Manders, Evert
- Berg, Sibren van den
- Deesker, Lisa J.
- Garrelfs, Sander F.
- Visser, Saco J. de
- Groothoff, Jaap W.
- Hollak, Carla E. M.
- SpringerLink (Online service)
Other Objects (12)
A Framework for the Fair Pricing of Medicines
Pricing and reimbursement of orphan drugs: the need for more transparency
Public spending on orphan medicines: a review of the literature
Variables affecting pricing of orphan drugs: the Italian case
Estimating the budget impact of orphan medicines in Europe: 2010 - 2020
Price tagging the priceless: International reference pricing for medicines in theory and practice
Towards ethical drug pricing: the European Orphan Genomic Therapies Fund
Forming a medicines pricing policy for low and middle-income countries (LMICs): the case for Pakistan
Shining a light in the black box of orphan drug pricing
Understanding the trends in international agreements on pricing and reimbursement for newly marketed medicines and their implications for access to medicines: a computational text analysis
Estimating the clinical cost of drug development for orphan versus non-orphan drugs
Use of biomarkers in the context of orphan medicines designation in the European Union
A Framework for the Fair Pricing of Medicines
Pricing and reimbursement of orphan drugs: the need for more transparency
Public spending on orphan medicines: a review of the literature
Variables affecting pricing of orphan drugs: the Italian case
Estimating the budget impact of orphan medicines in Europe: 2010 - 2020
Price tagging the priceless: International reference pricing for medicines in theory and practice
Towards ethical drug pricing: the European Orphan Genomic Therapies Fund
Forming a medicines pricing policy for low and middle-income countries (LMICs): the case for Pakistan
Shining a light in the black box of orphan drug pricing
Understanding the trends in international agreements on pricing and reimbursement for newly marketed medicines and their implications for access to medicines: a computational text analysis
Estimating the clinical cost of drug development for orphan versus non-orphan drugs
Use of biomarkers in the context of orphan medicines designation in the European Union
A Framework for the Fair Pricing of Medicines
Pricing and reimbursement of orphan drugs: the need for more transparency
Public spending on orphan medicines: a review of the literature
Variables affecting pricing of orphan drugs: the Italian case
Estimating the budget impact of orphan medicines in Europe: 2010 - 2020
Price tagging the priceless: International reference pricing for medicines in theory and practice
Towards ethical drug pricing: the European Orphan Genomic Therapies Fund
Forming a medicines pricing policy for low and middle-income countries (LMICs): the case for Pakistan
Shining a light in the black box of orphan drug pricing
Understanding the trends in international agreements on pricing and reimbursement for newly marketed medicines and their implications for access to medicines: a computational text analysis
Estimating the clinical cost of drug development for orphan versus non-orphan drugs